Trial Profile
Comparing Incidence of Serious Adverse Events Between Laninamivir and Non-User of Neuraminidase Inhibitor in Influenza Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Oct 2015
Price :
$35
*
At a glance
- Drugs Laninamivir (Primary) ; Antivirals
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Company
- 07 Oct 2015 New trial record
- 26 Aug 2015 Results presented at the 31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management.